# A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

> clinical trial · VERIFIED · 2026-07-20

Status: RECRUITING · Sponsor: AstraZeneca · Condition: Breast Cancer, Early Breast Cancer

- Company: AstraZeneca
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT05774951

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.